sr141716 has been researched along with slv 319 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adolfs, TJ; Coolen, HK; de Jong, NM; den Hartog, AP; Dijksman, JA; Herremans, AH; Hoogendoorn, J; Keizer, HG; Kruse, CG; Lange, JH; McCreary, AC; Ronken, E; Stork, B; Tipker, K; van Stuivenberg, HH; Veerman, W; Verveer, PC; Wals, HC | 1 |
| Adolfs, TJ; Coolen, HK; Kruse, CG; Lange, JH; McCreary, AC; Stork, B; van Stuivenberg, HH; Veerman, W; Wals, HC | 1 |
| Feng, Y; Fong, TM; Goulet, MT; Hagmann, WK; Jewell, JP; Kumar, S; Lanza, TJ; Lao, J; Lin, LS; Liu, P; Marsh, DJ; Qi, H; Rosko, K; Samuel, K; Shah, SK; Shearman, LP; Shen, CP; Strack, A; Stribling, DS; Tong, X; Van der Ploeg, LH; Wang, J; Xiao, JC; Xu, SS; Yin, W | 1 |
| Allen, NH; Bentley, CH; Brooks, TD; Foloppe, N; Kennett, G; Knight, AR; Leonardi, S; Misra, A; Monck, NJ; Sellwood, DM | 1 |
| Alig, L; Alsenz, J; Andjelkovic, M; Bénardeau, A; Bendels, S; Bleicher, K; Bourson, A; David-Pierson, P; Guba, W; Hildbrand, S; Kube, D; Lübbers, T; Mayweg, AV; Narquizian, R; Neidhart, W; Nettekoven, M; Plancher, JM; Rocha, C; Rogers-Evans, M; Röver, S; Schneider, G; Taylor, S; Waldmeier, P | 1 |
| Boykow, GC; Chackalamannil, S; Duffy, RA; Madison, VS; Wang, H | 1 |
| Bülow, A; Burstein, ES; Craig, D; Currier, EA; Del Tredici, AL; Ek, F; Fejzic, A; Gardell, LR; Jensen, J; Ma, JN; McFarland, K; Olsson, R; Ott, TR; Ottesen, LK; Pettersson, H; Piu, F; Tabatabaei, A | 1 |
| Benwell, K; Brooks, TD; Foloppe, N; Kennett, G; Knight, AR; Misra, A; Monck, NJ | 1 |
| Behnia, K; Carlson, KE; Ewing, WR; Gu, Z; Hong, Y; Johnghar, S; Keim, WJ; Miller, KJ; Murugesan, N; O'Tanyi, E; Pelleymounter, MA; Rohrbach, KW; Tian, Y; Yang, Y; Zhu, Y | 1 |
| Chorvat, RJ | 1 |
1 review(s) available for sr141716 and slv 319
| Article | Year |
|---|---|
Peripherally restricted CB1 receptor blockers.
Topics: Animals; Brain; Cocaine; Drug Discovery; Humans; Liver Diseases; Metabolic Diseases; Morpholines; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sulfonamides | 2013 |
9 other study(ies) available for sr141716 and slv 319
| Article | Year |
|---|---|
Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.
Topics: Administration, Oral; Animals; Arachidonic Acid; Binding, Competitive; Biological Availability; CHO Cells; Cricetinae; Crystallography, X-Ray; Fever; Humans; Hypotension; Male; Mice; Models, Molecular; Molecular Conformation; Pyrazoles; Radioligand Assay; Rats; Receptor, Cannabinoid, CB1; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2004 |
Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity.
Topics: Cannabinoids; Humans; Hydrophobic and Hydrophilic Interactions; Molecular Structure; Pyrazoles; Receptor, Cannabinoid, CB1; Stereoisomerism; Structure-Activity Relationship; Sulfonamides; X-Ray Diffraction | 2005 |
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Body Weight; Cannabinoids; Cyclic AMP; Eating; Humans; Liver; Microsomes; Obesity; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2006 |
Discovery of a novel class of selective human CB1 inverse agonists.
Topics: Cannabinoids; Combinatorial Chemistry Techniques; Drug Design; Humans; Ligands; Molecular Structure; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2008 |
Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Benzodioxoles; Body Weight; Crystallography, X-Ray; Cyclohexanols; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Hypothermia; Ligands; Male; Mice; Microsomes; Models, Molecular; Molecular Structure; Obesity; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Structure-Activity Relationship | 2008 |
Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model.
Topics: Bayes Theorem; Drug Evaluation, Preclinical; Models, Molecular; Protein Binding; Receptor, Cannabinoid, CB1 | 2008 |
Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Cell Line; Combinatorial Chemistry Techniques; Dibenzothiazepines; Drug Inverse Agonism; Eating; Humans; Hypothermia; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Models, Molecular; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Solubility; Structure-Activity Relationship; Thiazepines | 2009 |
Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.
Topics: Animals; Cannabinoids; Cannabis; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Humans; Ligands; Mice; Models, Chemical; Molecular Structure; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant | 2009 |
Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies.
Topics: Animals; Anti-Obesity Agents; Brain; Humans; Obesity; Radiography; Radioligand Assay; Rats; Receptor, Cannabinoid, CB1 | 2011 |